Fig. 6: Expression of NIK is associated with expression of PUM1-TRAF3 fusion and prognosis in patients with BTC. | npj Precision Oncology

Fig. 6: Expression of NIK is associated with expression of PUM1-TRAF3 fusion and prognosis in patients with BTC.

From: PUM1-TRAF3 fusion protein activates non-canonical NF-κB signaling via rescued NIK in biliary tract cancer

Fig. 6

a Representative images of NIK expression by immunohistochemistry in patients with BTC. NIK. NIK staining was scored as an intensity of NIK-positive (+) tumor cells: no expression: 0, low expression: 1+, moderate expression: 2+, and strong expression: 3+. 0 or 1+ was considered as NIK-weak whereas 2+ or 3 + IHC staining scores of NIK was considered NIK-strong group. b Relative frequency of NIK-weak (n = 35) and NIK-strong (n = 20) groups according to the PUM1-TRAF3 fusion status. c Kaplan–Meier analysis for survival according to PUM1-TRAF3 fusion in patients with BTC (n = 55). Disease-free survival (DFS) and overall survival (OS) were not significantly different between fusion-negative (n = 50) and fusion-positive group (n = 5). d Kaplan–Meier analysis for survival according to NIK expression in patients with BTC (n = 55). NIK-weak group (n = 35) presented significantly prolonged survival in DFS and OS compared to NIK-strong group (n = 20). e, f Forest plots for multivariate Cox proportional hazards analysis of the contribution of clinical factors to DFS and OS presented NIK-strong expression was significantly associated with poorer DFS and OS.

Back to article page